The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025. Tirzepatide is the ...

Mounjaro (tirzepatide) is a prescription drug used to help manage blood sugar levels in adults with type 2 diabetes. Mounjaro comes as an injection that’s given under your skin. This medication ...

Tirzepatide has been studied in weight management in 2 large, phase 3 studies: SURMOUNT‑1 (n=2,539) in people who did not have diabetes and SURMOUNT‑2 (n=938) in people with type 2 diabetes. Both ...

Shortly after the OFA filed its lawsuit, the FDA said it would review its decision to remove Lilly’s tirzepatide products from its shortage list—though the agency ultimately stuck by its ...

Tirzepatide may be more effective than semaglutide or liraglutide for weight loss, as it has a dual mechanism of action.

The FDA announced that the tirzepatide injection shortage is resolved. Hims & Hers Health, Inc.'s stock fell 6.90%, reflecting market concerns over regulatory updates and supply chain stability.

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...

In 2024, a warning by the U.S. Food and Drug Administration (FDA) focused on the potential dangers of compounded semaglutide and tirzepatide, with the agency citing reports of unanticipated health ...

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...

Tirzepatide, the active ingredient in Zepbound and Mounjaro, is no longer in short supply, the FDA says. Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025 ...